FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507865599> ?p ?o ?g. }

• W2507865599 endingPage "13153" @default.
• W2507865599 startingPage "13139" @default.
• W2507865599 abstract "// Judith E. Unterlass 1 , Arnaud Baslé 2 , Timothy J. Blackburn 3 , Julie Tucker 1 , Céline Cano 3 , Martin E.M. Noble 1 , Nicola J. Curtin 1 1 Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK 2 Institute of Cell and Molecular Biosciences, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK 3 Northern Institute for Cancer Research, School of Chemistry, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK Correspondence to: Martin E.M. Noble, email: martin.noble@ncl.ac.uk Keywords: cancer metabolism, PHGDH, serine metabolism, drug discovery, fragments Received: May 16, 2016     Accepted: July 13, 2016     Published: August 22, 2016 ABSTRACT 3-Phosphoglycerate dehydrogenase (PHGDH) has recently been identified as an attractive target in cancer therapy as it links upregulated glycolytic flux to increased biomass production in cancer cells. PHGDH catalyses the first step in the serine synthesis pathway and thus diverts glycolytic flux into serine synthesis. We have used siRNA-mediated suppression of PHGDH expression to show that PHGDH is a potential therapeutic target in PHGDH -amplified breast cancer. Knockdown caused reduced proliferation in the PHGDH -amplified cell line MDA-MB-468, whereas breast cancer cells with low PHGDH expression or with elevated PHGDH expression in the absence of genomic amplification were not affected. As a first step towards design of a chemical probe for PHGDH, we report a fragment-based drug discovery approach for the identification of PHGDH inhibitors. We designed a truncated PHGDH construct that gave crystals which diffracted to high resolution, and could be used for fragment soaking. 15 fragments stabilising PHGDH were identified using a thermal shift assay and validated by X-ray crystallography and ITC competition experiments to exhibit 1.5-26.2 mM affinity for PHGDH. A structure-guided fragment growing approach was applied to the PHGDH binders from the initial screen, yielding greater understanding of the binding site and suggesting routes to achieve higher affinity NAD-competitive inhibitors." @default.
• W2507865599 created "2016-09-16" @default.
• W2507865599 creator A5012219762 @default.
• W2507865599 creator A5030796000 @default.
• W2507865599 creator A5032387920 @default.
• W2507865599 creator A5038524097 @default.
• W2507865599 creator A5061501904 @default.
• W2507865599 creator A5062324575 @default.
• W2507865599 creator A5078994565 @default.
• W2507865599 date "2016-08-22" @default.
• W2507865599 modified "2023-09-26" @default.
• W2507865599 title "Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer" @default.
• W2507865599 cites W1503873678 @default.
• W2507865599 cites W1916946492 @default.
• W2507865599 cites W1934493757 @default.
• W2507865599 cites W1965578150 @default.
• W2507865599 cites W1978347106 @default.
• W2507865599 cites W1979511656 @default.
• W2507865599 cites W1985690173 @default.
• W2507865599 cites W1996100382 @default.
• W2507865599 cites W2001641653 @default.
• W2507865599 cites W2003464399 @default.
• W2507865599 cites W2006922696 @default.
• W2507865599 cites W2013535962 @default.
• W2507865599 cites W2014460958 @default.
• W2507865599 cites W2019432874 @default.
• W2507865599 cites W2022643459 @default.
• W2507865599 cites W2022899908 @default.
• W2507865599 cites W2025600760 @default.
• W2507865599 cites W2028816469 @default.
• W2507865599 cites W2035805526 @default.
• W2507865599 cites W2038840577 @default.
• W2507865599 cites W2043585619 @default.
• W2507865599 cites W2064144156 @default.
• W2507865599 cites W2097259163 @default.
• W2507865599 cites W2124026197 @default.
• W2507865599 cites W2126524529 @default.
• W2507865599 cites W2170048458 @default.
• W2507865599 cites W2266570683 @default.
• W2507865599 cites W2464879055 @default.
• W2507865599 cites W2480051333 @default.
• W2507865599 cites W4233548753 @default.
• W2507865599 cites W4362017974 @default.
• W2507865599 doi "https://doi.org/10.18632/oncotarget.11487" @default.
• W2507865599 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5862567" @default.
• W2507865599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29568346" @default.
• W2507865599 hasPublicationYear "2016" @default.
• W2507865599 type Work @default.
• W2507865599 sameAs 2507865599 @default.
• W2507865599 citedByCount "24" @default.
• W2507865599 countsByYear W25078655992016 @default.
• W2507865599 countsByYear W25078655992017 @default.
• W2507865599 countsByYear W25078655992018 @default.
• W2507865599 countsByYear W25078655992019 @default.
• W2507865599 countsByYear W25078655992020 @default.
• W2507865599 countsByYear W25078655992021 @default.
• W2507865599 countsByYear W25078655992022 @default.
• W2507865599 countsByYear W25078655992023 @default.
• W2507865599 crossrefType "journal-article" @default.
• W2507865599 hasAuthorship W2507865599A5012219762 @default.
• W2507865599 hasAuthorship W2507865599A5030796000 @default.
• W2507865599 hasAuthorship W2507865599A5032387920 @default.
• W2507865599 hasAuthorship W2507865599A5038524097 @default.
• W2507865599 hasAuthorship W2507865599A5061501904 @default.
• W2507865599 hasAuthorship W2507865599A5062324575 @default.
• W2507865599 hasAuthorship W2507865599A5078994565 @default.
• W2507865599 hasBestOaLocation W25078655991 @default.
• W2507865599 hasConcept C121608353 @default.
• W2507865599 hasConcept C173396325 @default.
• W2507865599 hasConcept C181199279 @default.
• W2507865599 hasConcept C190283241 @default.
• W2507865599 hasConcept C2776414213 @default.
• W2507865599 hasConcept C502942594 @default.
• W2507865599 hasConcept C54009773 @default.
• W2507865599 hasConcept C54355233 @default.
• W2507865599 hasConcept C55493867 @default.
• W2507865599 hasConcept C81885089 @default.
• W2507865599 hasConcept C86803240 @default.
• W2507865599 hasConcept C96232424 @default.
• W2507865599 hasConceptScore W2507865599C121608353 @default.
• W2507865599 hasConceptScore W2507865599C173396325 @default.
• W2507865599 hasConceptScore W2507865599C181199279 @default.
• W2507865599 hasConceptScore W2507865599C190283241 @default.
• W2507865599 hasConceptScore W2507865599C2776414213 @default.
• W2507865599 hasConceptScore W2507865599C502942594 @default.
• W2507865599 hasConceptScore W2507865599C54009773 @default.
• W2507865599 hasConceptScore W2507865599C54355233 @default.
• W2507865599 hasConceptScore W2507865599C55493867 @default.
• W2507865599 hasConceptScore W2507865599C81885089 @default.
• W2507865599 hasConceptScore W2507865599C86803240 @default.
• W2507865599 hasConceptScore W2507865599C96232424 @default.
• W2507865599 hasIssue "17" @default.
• W2507865599 hasLocation W25078655991 @default.
• W2507865599 hasLocation W25078655992 @default.
• W2507865599 hasLocation W25078655993 @default.
• W2507865599 hasLocation W25078655994 @default.
• W2507865599 hasLocation W25078655995 @default.
• W2507865599 hasOpenAccess W2507865599 @default.

• next